CCRM – Commercializing Living Therapies



CCRM is a Canadian, not-for-profit, public-private consortium supporting the development of foundational technologies that accelerate the commercialization of regenerative medicines,
including cell and gene therapies. Established in 2011 with funding from the federal government’s Networks of Centres of Excellence program, we bridge the regenerative medicine commercialization gap by leveraging funding and infrastructure, and mobilizing business and scientific expertise to translate technologies into new companies and revolutionary products that are accessible to patients.

These therapies and technologies have the potential to transform health care, with the promise to treat, manage and perhaps cure some of the most debilitating and costly diseases in the world today. Regenerative medicine aims to harness the power of stem cells, biomaterials and molecules to repair, regenerate or replace diseased cells, tissues and organs.

CCRM’s 40,000 square foot (4,000 square metre) facility in Toronto’s MaRS Discovery District houses a 10,000 square foot (930 square metre) laboratory that is based on a modular design, with a large, fully-flexible process hall for mimicking advanced biologics manufacturing workflows and practices. This process hall is central to the capabilities of the Centre for Advanced Therapeutic Cell Technologies (CATCT), which is an advanced manufacturing centre of excellence focused on addressing the many challenges associated with cell and gene therapy manufacturing.

CATCT is jointly supported by GE Healthcare and the Federal Economic Development Agency for Southern Ontario (FedDev Ontario), and was launched in January 2016 with an announcement from Rt. Hon. Justin Trudeau, Prime Minister of Canada (pictured above).


Twitter: @ccrm_ca